title: Guideline adherence in cardiovascular risk assessment and analysis in 15,000 hypertensive German patients in real life: results of the Prospective 3A Registry.
abstract: The benefit obtained from antihypertensive treatment is related more to overall cardiovascular risk reduction than to blood pressure levels. Accurate implementation of cardiovascular diagnostics is a key step toward assessment of cardiovascular risk. In the 3A Registry study, data about patient history, concomitant diseases, diagnostic procedures, and medications were prospectively collected. A total of 14,738 patients recruited by 899 physicians in 2008 and 2009 were analyzed. Assessment of cardiovascular risk factors and subclinical end-organ damage (SOD) showed broad differences in the implementation of European Society of Hypertension/European Society of Cardiology recommendations. Electrocardiograms were available in 59% of patients, cholesterol in 71.4%, and glucose in 69.7%. Almost all patients (99.6%) had creatinine measurements performed and microalbuminuria was measured in 8.5%. Metabolic syndrome (MS) had been evaluated in 59.7%. Implementation of diagnostic guidelines was highest in hypertensive patients with diabetes, followed by patients with known cardiovascular disease and established chronic renal insufficiency. For hypertensive patients without known comorbidities, the authors estimated that up to 29% had missed SOD (detection rate <50%) and 13% missed MS due to incomplete assessment of risk factors. This large registry study shows that assessment for cardiovascular risk factors and SOD is incomplete. Major efforts are required to improve comprehensive hypertension management as recommended by current guidelines.
authors.affiliation: HELIOS Klinikum Berlin-Buch and Experimental and Clinical Research Center, Charité University Hospital Berlin, Berlin, Germany. ralf.dechend@charite.de
authors.forename: Ralf
authors.initials: R
authors.lastname: Dechend
authors.forename: Edelgard
authors.initials: E
authors.lastname: Kaiser
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Derer
authors.forename: Evelin
authors.initials: E
authors.lastname: Deeg
authors.forename: Andreas
authors.initials: A
authors.lastname: Busjahn
authors.forename: Roland E
authors.initials: RE
authors.lastname: Schmieder
authors.forename: Uwe
authors.initials: U
authors.lastname: Zeymer
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000502:physiology; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D004562:Electrocardiography; D005858:Germany; D019983:Guideline Adherence; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012042:Registries; D018570:Risk Assessment
chemical_list: D000959:Antihypertensive Agents